Low-pass Whole-genome Sequencing of Circulating Cell-free DNA Demonstrates Dynamic Changes in Genomic Copy Number in a Squamous Lung Cancer Clinical Cohort

We developed a method to monitor copy number variations (CNV) in plasma cell-free DNA (cfDNA) from patients with metastatic squamous non-small cell lung cancer (NSCLC). We aimed to explore the association between tumor-derived cfDNA and clinical outcomes, and sought CNVs that may suggest potential r...

Full description

Saved in:
Bibliographic Details
Published in:Clinical cancer research 2019-04, Vol.25 (7), p.2254-2263
Main Authors: Chen, Xiaoji, Chang, Ching-Wei, Spoerke, Jill M, Yoh, Kathryn E, Kapoor, Vidushi, Baudo, Charles, Aimi, Junko, Yu, Mamie, Liang-Chu, May M Y, Suttmann, Rebecca, Huw, Ling-Yuh, Gendreau, Steven, Cummings, Craig, Lackner, Mark R
Format: Article
Language:English
Subjects:
Biomarkers, Tumor
Carcinoma, Squamous Cell - diagnosis
Carcinoma, Squamous Cell - drug therapy
Carcinoma, Squamous Cell - genetics
Carcinoma, Squamous Cell - mortality
Cell Line, Tumor
Circulating Tumor DNA
Cohort Studies
DNA Copy Number Variations
Drug Resistance, Neoplasm - drug effects
Drug Resistance, Neoplasm - genetics
Genome, Human
Genomics - methods
High-Throughput Nucleotide Sequencing
Humans
Lung Neoplasms - diagnosis
Lung Neoplasms - drug therapy
Lung Neoplasms - genetics
Lung Neoplasms - mortality
Molecular Targeted Therapy
Polymorphism, Single Nucleotide
Prognosis
Sequence Analysis, DNA
Whole Genome Sequencing
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We developed a method to monitor copy number variations (CNV) in plasma cell-free DNA (cfDNA) from patients with metastatic squamous non-small cell lung cancer (NSCLC). We aimed to explore the association between tumor-derived cfDNA and clinical outcomes, and sought CNVs that may suggest potential resistance mechanisms. Sensitivity and specificity of low-pass whole-genome sequencing (LP-WGS) were first determined using cell line DNA and cfDNA. LP-WGS was performed on baseline and longitudinal cfDNA of 152 patients with squamous NSCLC treated with chemotherapy, or in combination with pictilisib, a pan-PI3K inhibitor. cfDNA tumor fraction and detected CNVs were analyzed in association with clinical outcomes. LP-WGS successfully detected CNVs in cfDNA with tumor fraction ≥10%, which represented approximately 30% of the first-line NSCLC patients in this study. The most frequent CNVs were gains in chromosome 3q, which harbors the and oncogenes. The CNV landscape in cfDNA with a high tumor fraction generally matched that of corresponding tumor tissue. Tumor fraction in cfDNA was dynamic during treatment, and increases in tumor fraction and corresponding CNVs could be detected before radiographic progression in 7 of 12 patients. Recurrent CNVs, such as amplification, were enriched in cfDNA from posttreatment samples compared with the baseline, suggesting a potential resistance mechanism to pictilisib. LP-WGS offers an unbiased and high-throughput way to investigate CNVs and tumor fraction in cfDNA of patients with cancer. It may also be valuable for monitoring treatment response, detecting disease progression early, and identifying emergent clones associated with therapeutic resistance.
ISSN:1078-0432
1557-3265
DOI:10.1158/1078-0432.CCR-18-1593